Literature DB >> 22139204

[Tuberculosis : diagnostics and prophylaxis].

N Görl1, R Diel, C Kneitz.   

Abstract

Infection with Mycobacterium tuberculosis causes primarily formation of granulomatous tubercles in the lungs. In the absence of any clinical symptoms it is named latent tuberculosis infection which can be an origin of reactivation, especially as a consequence of an impaired response of the immune system. Complete anamnesis, radiographic methods and bacteriological analysis (microscopy, culture, PCR) are useful for diagnosis of tuberculosis. Since 2005 newer in vitro tests are available using interferon-gamma release assays (IGRAs). Compared to the tuberculin skin test it is possible to differentiate between infection with M. tuberculosis and individuals vaccinated with the Bacillus Calmette-Guérin (BCG) vaccine. These new in vitro tests are part of a screening procedure which has to be performed before starting immunosuppressive therapy with tumor necrosis factor-alpha (TNF-α) inhibitors. In cases of latent tuberculosis infection administration of isoniazid for 9 months is recommended.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22139204     DOI: 10.1007/s00393-011-0921-4

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  18 in total

Review 1.  Immunology of tuberculosis.

Authors:  J L Flynn; J Chan
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  [New recommendations for contact tracing in tuberculosis. German Central Committee against Tuberculosis].

Authors:  R Diel; G Loytved; A Nienhaus; S Castell; A Detjen; H Geerdes-Fenge; W Haas; B Hauer; B Königstein; D Maffei; K Magdorf; M Priwitzer; J-P Zellweger; R Loddenkemper
Journal:  Pneumologie       Date:  2011-05-10

3.  Influence of bacille Calmette-Guérin vaccination on size of tuberculin skin test reaction: to what size?

Authors:  F Tissot; G Zanetti; P Francioli; J-P Zellweger; F Zysset
Journal:  Clin Infect Dis       Date:  2004-12-20       Impact factor: 9.079

4.  Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?

Authors:  Stefan Ehlers
Journal:  Clin Infect Dis       Date:  2005-08-01       Impact factor: 9.079

5.  [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].

Authors:  R Diel; B Hauer; R Loddenkemper; B Manger; K Krüger
Journal:  Z Rheumatol       Date:  2009-07       Impact factor: 1.372

6.  Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis.

Authors:  Roland Diel; Robert Loddenkemper; Karen Meywald-Walter; Stefan Niemann; Albert Nienhaus
Journal:  Am J Respir Crit Care Med       Date:  2008-02-14       Impact factor: 21.405

Review 7.  Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies.

Authors:  Joseph Keane; Barry Bresnihan
Journal:  Curr Opin Rheumatol       Date:  2008-07       Impact factor: 5.006

Review 8.  Novel screening tools for latent tuberculosis: time to leave an old friend?

Authors:  Peter M Villiger; Jean-Pierre Zellweger; Burkhard Möller
Journal:  Curr Opin Rheumatol       Date:  2009-05       Impact factor: 5.006

9.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Authors:  R S Wallis; M S Broder; J Y Wong; M E Hanson; D O Beenhouwer
Journal:  Clin Infect Dis       Date:  2004-04-15       Impact factor: 9.079

10.  An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.

Authors:  Matthew P R Berry; Christine M Graham; Finlay W McNab; Zhaohui Xu; Susannah A A Bloch; Tolu Oni; Katalin A Wilkinson; Romain Banchereau; Jason Skinner; Robert J Wilkinson; Charles Quinn; Derek Blankenship; Ranju Dhawan; John J Cush; Asuncion Mejias; Octavio Ramilo; Onn M Kon; Virginia Pascual; Jacques Banchereau; Damien Chaussabel; Anne O'Garra
Journal:  Nature       Date:  2010-08-19       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.